*** Welcome to piglix ***

Ustekinumab

Ustekinumab
Monoclonal antibody
Type Whole antibody
Source Human
Target IL-12 and IL-23
Clinical data
Trade names Stelara
AHFS/Drugs.com Monograph
MedlinePlus a611013
License data
Pregnancy
category
  • contraindicated
Routes of
administration
subcutaneous injection
ATC code
Legal status
Legal status
Pharmacokinetic data
Metabolism unknown
Biological half-life 15–32 days (average 3 weeks)
Identifiers
Synonyms CNTO 1275
CAS Number
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C6482H10004N1712O2016S46
Molar mass 145.64 kg/mol
 NYesY (what is this?)  

Ustekinumab, sold under the brand name Stelara, is a human monoclonal antibody used to treat psoriasis.

It is manufactured in the Netherlands. It is directed against interleukin 12 and interleukin 23, naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders.

It was found not effective for multiple sclerosis.

Ustekinumab is used to treat psoriasis. This includes psoriatic arthritis and when it affects the skin.

CNTO 1275 is designed to interfere with the triggering of the body's inflammatory response through the suppression of certain cytokines. Specifically, CNTO 1275 blocks interleukin IL-12 and IL-23 which help activate certain T-cells. It binds to the p-40 subunit of both IL-12 and IL-23 so that they subsequently cannot bind to their receptors.

According to information provided by Centocor, maker of one medication based on ustekinumab, their version of the drug is associated with several types of serious adverse effects. These include an increased risk of infection, such as by tuberculosis and an increased risk of certain types of cancer. As with some other immunosuppressant drugs like ciclosporin, the brain swelling of posterior reversible encephalopathy syndrome is a risk. The pharmaceutical company also reports serious allergic reaction as a possible side effect. More common side effects are upper respiratory infection, headache, and tiredness.


...
Wikipedia

...